Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
November 30, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya®* (cyclobenzaprine HCI sublingual tablets), or...
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
November 07, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Enrolling Phase 3 HONOR study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) in Military-Related PTSD: Interim Analysis Expected 1H18 and Topline Results Expected 2H18 Formal FDA Feedback on...
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
November 01, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
October 17, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address...
Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
October 12, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
September 29, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
September 14, 2017 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
September 14, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya®* (cyclobenzaprine HCI sublingual tablets), or...
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 06, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
August 29, 2017 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 2 Study of U.S. FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in PTSD Indicates Early Sleep Quality Improvements Correlate with Later Response to Treatment...